Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: August 30, 2022 Report Code: GDGMDHC22306IDB-ST

Select Item

Stroke can occur with symptoms including sudden numbness in their face or limbs, particularly down one side of their body. The sufferer may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.

The Stroke pipeline drugs market research report outlays comprehensive information on the Stroke targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in Stroke targeted therapeutics development with respective active and dormant or discontinued projects.

Stroke Pipeline Drugs Market Segmentation by Targets

Some of the primary targets in the Stroke pipeline drugs market are Free Radical, Plasminogen, Disks Large Homolog, Tissue Type Plasminogen Activator, Platelet Glycoprotein VI, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12, Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, Sigma Non Opioid Intracellular Receptor, Coagulation Factor XI. Free Radical accounted for the largest target in the Stroke pipeline drugs market.

Stroke Pipeline Drugs Market Analysis, by Targets

Stroke Pipeline Drugs Market Analysis, by Targets

To know more about the targets in the Stroke pipeline drugs market, download a free report sample

Stroke Pipeline Drugs Market Segmentation by Mechanisms of Action

The primary mechanisms of action in the Stroke pipeline drugs market are Free Radical Scavenger, Plasminogen Activator, Disks Large Homolog 4 Inhibitor, Platelet Glycoprotein VI Inhibitor, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12, Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2YAntagonist, Sigma NonOpioid Intracellular Receptor 1 Agonist, Tissue Type Plasminogen Activator Replacement. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor has the maximum number of products in the Stroke pipeline drugs market.

Stroke Pipeline Drugs Market Analysis, by Mechanisms of Action

Stroke Pipeline Drugs Market Analysis, by Mechanisms of Action

To know more about the MoA in the Stroke pipeline drugs market, download a free report sample

Stroke Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Stroke pipeline drugs market are intravenous, oral, subcutaneous, parenteral, topical, intraarticular, intrathecal, and sublingual. Intravenous has the majority number of products in the Stroke pipeline drugs market.

Stroke Pipeline Drugs Market Analysis, by Routes of Administration

Stroke Pipeline Drugs Market Analysis, by Routes of Administration

To know more about the RoA in the Stroke pipeline drugs market, download a free report sample

Stroke Pipeline Drugs Market Segmentation by Molecule Type

The key molecule types in the Stroke pipeline drugs market are Small Molecule, Monoclonal Antibody, Cell Therapy, Recombinant Protein, Biologic, Synthetic Peptide, and Protein among others.

Stroke Pipeline Drugs Market Analysis, by Molecule Type

Stroke Pipeline Drugs Market Analysis, by Molecule Type

To know more about the molecule type in the Stroke pipeline drugs market, download a free report sample

Competitive Landscape

Some of the leading companies in the Stroke pipeline drugs market are NoNO Inc, Primary Peptides Inc, Yantai YenePharma Co Ltd, APT Therapeutics Inc, ArmaGen Inc, Biogen Inc, CHA Biotech Co Ltd, and M3 Therapeutics Inc among others. NoNO Inc accounted for the largest Stroke pipeline drugs market share in 2021.

Stroke Pipeline Drugs Market Analysis, by Leading Companies

Stroke Pipeline Drugs Market Analysis, by Leading Companies

To know more about the leading companies in the Stroke pipeline drugs market, download a free report sample

Stroke Pipeline Drugs Market Report Overview

Key Targets Free Radical, Plasminogen, Disks Large Homolog, Tissue Type Plasminogen Activator, Platelet Glycoprotein VI, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12, Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, Sigma Non Opioid Intracellular Receptor, Coagulation Factor XI
Key Mechanisms of Action Free Radical Scavenger, Plasminogen Activator, Disks Large Homolog 4 Inhibitor, Platelet Glycoprotein VI Inhibitor, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12, Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2YAntagonist, Sigma Non Opioid Intracellular Receptor 1 Agonist, Tissue Type Plasminogen Activator Replacement
Key Routes of Administration Intravenous, Oral, Subcutaneous, Parenteral, Topical, Intraarticular, Intrathecal, and Sublingual
Key Molecule Types Small Molecule, Monoclonal Antibody, Cell Therapy, Recombinant Protein, Biologic, Synthetic Peptide, and Protein
Leading Companies NoNO Inc, Primary Peptides Inc, Yantai YenePharma Co Ltd, APT Therapeutics Inc, ArmaGen Inc, Biogen Inc, CHA Biotech Co Ltd, and M3 Therapeutics Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

4B Technologies (Suzhou) Co Ltd
AbbVie Inc
Acticor Biotech SAS
advanceCor GmbH
Advanced BioMatrix Inc
AegisCN LLC
Aegle Therapeutics Corp
Akome Biotech Ltd
AlaMab Therapeutics Inc
Algernon Pharmaceuticals Inc
Allife Medical Science and Technology Co Ltd
Anavex Life Sciences Corp
Angion Biomedica Corp
Ankasa Regenerative Therapeutics Inc
Annovis Bio Inc
Anthos Therapeutics Inc
AntiRadical Therapeutics LLC
Apellis Pharmaceuticals Inc
Aposcience AG
APstem Therapeutics Inc
APT Therapeutics Inc
AptaTargets SL
Argenica Therapeutics Ltd
AriBio
ArmaGen Inc
ArunA Bio Inc
Asdera LLC
Asha Therapeutics LLC
AstraZeneca Plc
Astrocyte Pharmaceuticals Inc
Athersys Inc
Avilex Pharma ApS
Axolo Pharma Inc
Band Therapeutics LLC
Basking Biosciences Inc
Bayer AG
Baylx Inc
Beijing Darwin Cell Biotechnology Co Ltd
Beijing Yinfeng Dingcheng Bioengineering Co Ltd
Bilix Co Ltd
Bio-Synectics Inc
Biogen Inc
Biosios (Beijing) Biotechnology Co Ltd
Bioxytran Inc
Bolden Therapeutics Inc
Bopin (Shanghai) Biomedical Technology Co Ltd
Brain-Gen LLC
Bristol-Myers Squibb Co
Cenyx Biotech Inc
CHA Biotech Co Ltd
Changzhou Qianhong Bio-Pharma Co Ltd
Chengdu Aoda Biotechnology Co Ltd
Chengdu Shibeikang Biomedical Technology Co Ltd
China Resources Emde Biological Pharmaceutical Co Ltd
Clinuvel Pharmaceuticals Ltd
Cogentis Therapeutics Inc
CohBar Inc
Constant Therapeutics LLC
Creative Medical Technology Holdings Inc
Crioestaminal Saude e Tecnologia SA
Daewoong Pharmaceutical Co Ltd
Deha Pharmaceutical LLC
Diapin Therapeutics LLC
DR.Noah Biotech Inc
Edvince AB
Egret Therapeutics Inc
Eight Plus One Pharmaceutical Co Ltd
EIP Pharma LLC
Elevian Inc
Emerald Organic Products Inc
Epigen Biosciences Inc
Epygen Biotech Pvt Ltd
Ever Supreme Bio Technology Co Ltd
Evgen Pharma Plc
Exscien Corp
F. Hoffmann-La Roche Ltd
Fortuna Fix Inc
Freeox Biotech SL
FUJIFILM Toyama Chemical Co Ltd
GABA Therapeutics Inc
Genentech USA Inc
Genervon Biopharmaceuticals LLC
Glucox Biotech AB
GNT Pharma Co Ltd
Guangzhou Cellprotek Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Guangzhou Recomgen Biotech Co Ltd
Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd
Gwoxi Stem Cell Applied Technology Co Ltd
Haimen Shengyuan Stem Cell Technology Co Ltd
Hefei Medical & Pharmaceutical Co Ltd
Help Therapeutics
Hemostemix Inc
Henan Genuine Biotech Co Ltd
Hibernaid Inc
Hillhurst Biopharmaceuticals Inc
Hopstem Biotechnology LLC
Hoth Therapeutics Inc
Immunwork Inc
Imstem Biotechnology Inc
Infensa Bioscience Pty Ltd
Inflammx Therapeutics Inc
Instituto Biomar SA
International Stem Cell Corp
Io Therapeutics Inc
IPCA Laboratories Ltd
Jeil Pharmaceutical Co Ltd
Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Ouwei Pharmaceutical Co Ltd
Jiangsu Wangao Pharmaceutical Co Ltd
JT Pharmaceuticals Inc
Kai Nuo Bio Sci Co Ltd
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings Inc
LTT Bio-Pharma Co Ltd
Lumosa Therapeutics Co Ltd
Lys Therapeutics SAS
M et P Pharma AG
M3 Therapeutics Inc
Mapreg SAS
Marizyme Inc
MD Healthcare Inc
Meridigen Biotech Co Ltd
MetiMedi Pharmaceuticals Co Ltd
Mitoconix Bio Ltd
Modulation Therapeutics Inc
NA Vaccine Research Institute Co Ltd
Nanjing Ningdan New Drug Technology Co Ltd
NC Medical Research Inc
NervGen Pharma Corp
NeuExcell Therapeutics Inc
Neuraly Inc
Neuren Pharmaceuticals Ltd
Neurevo GmbH
Neurexis Therapeutics Inc
NeurExo Sciences LLC
Neurodon LLC
NeuroNascent Inc
Neurondawn pharmaceutical Co Ltd
NeurOp Inc
Neurophyxia BV
NeuroTrauma Sciences LLC
New World Laboratories Inc
Nipro Corp
NoNO Inc
Novago Therapeutics AG
Novartis AG
NuvOx Pharma LLC
Nyrada Inc
Oasis Pharmaceuticals LLC
Omniox Inc
OTR3 SAS
Oxitope Pharma BV
Palisade Bio, Inc
Paracelsus Neuroscience I LLC
Pharmadrug Inc
Pharmagenesis Inc
PharmaTher Holdings Ltd
PharmatrophiX Inc
Pharmazz Inc
Pharmicell Co Ltd
Pharming Group NV
Phoenix Biotechnology Inc
PhytoHealth Corp
Prediction BioSciences SAS
Primary Peptides Inc
Prolong Pharmaceuticals LLC
Protheragen Inc
Q Therapeutics Inc
Q32 Bio Inc
Qingdao Primedicine Pharmaceutical Technology Co Ltd
Regenera Pharma Ltd
Regeneron Pharmaceuticals Inc
RegeneRx Biopharmaceuticals Inc
Reliance Life Sciences Pvt Ltd
Remedium Bio Inc
ReNetX Bio
ReNeuron Group Plc
Revalesio Corp
Revive Therapeutics Ltd
Rubicon Biotechnology Inc
S&E Bio Co Ltd
S.Biomedics Co Ltd
Saillant Therapeutics BV
Saje Pharma LLC
SanBio Co Ltd
Saneron CCEL Therapeutics Inc
Saniona AB
Sansho Co Ltd
Savara Inc
Sentan Pharma Inc
Serenity Bioworks Inc
Shanghai Hutchison Pharmaceuticals Ltd
Shanghai SIMR Biotech Co Ltd
Shanghai Zhimeng Biopharma Inc
Shijiazhuang Yiling Pharmaceutical Co Ltd
Shimao Tianjie Pharmaceutical (Jiangsu) Co Ltd
Shin Poong Pharm Co Ltd
Shionogi & Co Ltd
Silver Creek Pharmaceuticals Inc
Simcere Pharmaceutical Co Ltd
SL Bigen Co Ltd
SNJ Pharma Inc
Stemedica Cell Technologies Inc
Stemetix Inc
Stream Biomedical Inc
SunBio Inc
Suzhou Auzone Biological Technology Co Ltd
Suzhou Pharmavan Cancer Research Center Co Ltd
Synaptogenix Inc
TagCyx Biotechnologies
TargED Biopharmaceuticals BV
Tasly Pharmaceutical Group Co Ltd
Techfields Pharma Co Ltd
The Cell Factory BVBA
Theertha Biopharma Pvt Ltd
TheraSource LLC
Theratome Bio Inc
Thrombolytic Science International LLC
TikoMed AB
Translational Sciences Inc
TrueBinding Inc
Valin Technologies Ltd
Vanworld Pharmaceutical (Rugao) Company Ltd
Vect-Horus SAS
Venturis Therapeutics Inc
Verseon Corp
Virogenomics BioDevelopment Inc
Virtici LLC
Vitro Biopharma Inc
Vivazome Therapeutics Pty Ltd
XBiotech Inc
Xonovo Inc
Yantai YenePharma Co Ltd
YouCare Pharmaceutical Group Co Ltd
Zensun (Shanghai) Sci & Tech Co Ltd
Zhejiang Ausun Pharmaceutical Co Ltd
Zhittya Genesis Medicine Inc
Zocere Inc
ZyVersa Therapeutics Inc
ZZ Biotech LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Stroke – Overview

Stroke – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Stroke – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Stroke – Companies Involved in Therapeutics Development

Stroke – Drug Profiles

Stroke – Dormant Projects

Stroke – Discontinued Products

Stroke – Product Development Milestones

Featured News & Press Releases

Feb 17, 2017: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Stroke, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Products under Development by Universities/Institutes, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Stroke – Dormant Projects, 2022

Stroke – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Stroke, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the targets in the Stroke pipeline drugs market?

    Some of the targets in the Stroke pipeline drugs market are Free Radical, Plasminogen, Disks Large Homolog, Tissue Type Plasminogen Activator, Platelet Glycoprotein VI, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12, Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, Sigma Non Opioid Intracellular Receptor, Coagulation Factor XI among others.

  • What are the mechanisms of action in the Stroke pipeline drugs market?

    The primary mechanism of action in the Stroke pipeline drugs market are Free Radical Scavenger, Plasminogen Activator, Disks Large Homolog 4 Inhibitor, Platelet Glycoprotein VI Inhibitor, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12, Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2YAntagonist, Sigma Non Opioid Intracellular Receptor 1 Agonist, Tissue Type Plasminogen Activator Replacement among others.

  • What are the routes of administration in the Stroke pipeline drugs market?

    The routes of administration in the Stroke pipeline drugs market are intravenous, oral, subcutaneous, parenteral, topical, intraarticular, intrathecal, and sublingual among others.

  • What are the molecule types in the Stroke pipeline drugs market?

    The molecule types in the Stroke pipeline drugs market are Small Molecule, Monoclonal Antibody, Cell Therapy, Recombinant Protein, Biologic, Synthetic Peptide, and Protein among others.

  • Which are the leading companies in the Stroke pipeline drugs market?

    Some of the leading companies in the Stroke pipeline drugs market are NoNO Inc, Primary Peptides Inc, Yantai YenePharma Co Ltd, APT Therapeutics Inc, ArmaGen Inc, Biogen Inc, CHA Biotech Co Ltd, and M3 Therapeutics Inc among others.

Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Cardiovascular reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
$3,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more